ArticleBMC pediatrics2026
Comparative study of post- COVID-19 Kawasaki disease and multisystem inflammatory syndrome cases at Alexandria University Children's Hospital.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultisystem inflammatory syndrome in children (MIS-C) and Kawasaki disease (KD) share overlapping clinical features, and 25-50% of MIS-C cases may meet KD criteria. Differentiating between both conditions is clinically important for timely and appropriate management. The study aims to compare clinical manifestations, laboratory characteristics, clinical course, and outcomes of children diagnosed with post-COVID-19 MIS-C versus KD, and to develop a discrimination score to aid differentiation.
methodsThis retrospective study included 211 children admitted to Alexandria University Children's Hospital pediatric wards or Pediatric ICU from February 2023 to December 2024. Patients were classified as MIS-C/PIMS temporally associated with COVID-19 according to the COVID-19 study case definition, or as post-COVID-19 Kawasaki disease according to the American Heart Association diagnostic criteria for Kawasaki disease. Demographic, clinical, laboratory, and echocardiographic data were collected from medical records. Between-group comparisons were performed, and multivariate logistic regression was used to identify independent predictors and construct an exploratory clinical discrimination score. Diagnostic performance was assessed using ROC analysis.
resultsOf 211 children, 185 (87.7%) had MIS-C and 26 (12.3%) had KD. KD showed significantly higher rates of classic mucocutaneous features including conjunctivitis, stomatitis, lymphadenitis, and extremity edema (all p < .001). MIS-C was associated with significantly higher rates of shock (49.7% vs. 7.7%, p < .001), renal involvement (impairment 42.7% vs. 7.7%, p < .001; proteinuria 40.5% vs. 11.5%, p = .004; hematuria 31.9% vs. 3.8%, p = .002), hepatitis (64.9% vs. 30.8%, p < .001), and neurological involvement including altered level of consciousness (49.7% vs. 7.7%, p < .001). Cardiac involvement differed: myocarditis was more frequent in MIS-C (63.2% vs. 11.5%, p < .001), whereas coronary artery involvement was observed only in KD (15.4% vs. 0%, p < .001) and valvular lesions were more common in KD (80.8% vs. 51.4%, p = .004). A discrimination score demonstrated excellent performance (AUC 0.934; 95% CI 0.876-0.991; p < .001); at a cutoff > 3 points, sensitivity was 94.05% and specificity 84.62%. Mortality occurred in 13 MIS-C patients (7.0%) while all KD patients survived.
conclusionsIn this single-center cohort, the observed differences between MIS-C and Kawasaki disease largely confirm previously reported patterns, with MIS-C showing more frequent shock, renal and neurological involvement, hepatitis, and myocarditis, while Kawasaki disease showed more prominent mucocutaneous and coronary involvement. The proposed discrimination score showed promising exploratory performance in this cohort; however, it requires prospective and external validation before routine clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.